Search

Displaying results 2911 - 2920 of 10000 in total
  1. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

    Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 Substrates
  2. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  3. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    cells to promote T cell–mediated cytotoxicity. … [A253587] Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds,[A253587, L43622] allowing the drug to recruit CD3-expressing T cells to BCMA-expressing

    Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
  4. Indication

    Immune Thrombocytopenia (ITP)

    go.drugbank.com/conditions/DBCOND0035132
    Drugs: Azathioprine · Cortisone acetate · Cyclosporine · Dexamethasone · Hydrocortisone · Hydrocortisone succinate +6 more
    Synonyms: Thrombocytopenia due to immune destruction, Thrombocytopenia due to immune destruction, NOS
  5. Indication

    Post Polycythemia Vera Myelofibrosis

    go.drugbank.com/conditions/DBCOND0062303
    Drugs: Ruxolitinib
    Synonyms: Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis due to and following polycythaemia vera
  6. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.

    Mixtures: DIPIRONA 300 MG + ISOMETEPTENO 50 MG + CAFEINA 30 MG GOTAS, DIPIRONA SODICA 300 MG/ ISOMETEPTENO CLORHIDRATO 50 MG / CAFEINA 30 MG GOTAS
  7. Indication

    Deficiency of the interleukin-1 receptor antagonist

    go.drugbank.com/conditions/DBCOND0008480
    Drugs: Anakinra · Rilonacept
    Synonyms: Autoinflammatory disease due to interleukin-1 receptor antagonist deficiency
  8. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  9. Indication

    Restlessness

    go.drugbank.com/conditions/DBCOND0017791
    Drugs: Chlorpromazine
    Synonyms: Unable to keep still
  10. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy. … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.